Overview
| Generic Names: | Alotano [Dcit]; Bromchlortrifluoraethanum; Bromochlorotrifluoroethane; Cf3chclbr; Fluorotane; Fluorothane; Freon 123b1; Ftorotan [Russian]; Ftuorotan; Halotano [INN-Spanish]; Halothan; Halothanum [INN-Latin]; Narcotann Ne-Spofa [Russian] |
|---|---|
| Trade Names: | Anestan; Chalothane; Fluktan; Fluothane; Halan; Halotan; Halothane; Halsan; Narcotan; Narcotane; Narkotan; Phthorothanum; Rhodialothan |
| PharmGKB Accession Id: | PA449845 |
Description
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) (source: Drug Bank)
Indication
For the induction and maintenance of general anesthesia (source: Drug Bank)
ATC Therapeutic Category
- N01AB:Halogenated hydrocarbons
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Halothane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Halothane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. Also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Halothane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor. (source: Drug Bank)
Pharmacology
Halothane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It reduces the blood pressure and frequently decreases the pulse rate and depresses respiration. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. (source: Drug Bank)
Isomeric SMILES Code:
C(C(F)(F)F)(Cl)Br (source: Drug Bank)
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
CYP2A6 |
|
Publications |
|
CYP3A4 |
|
Publications |
|
|
RYR1 |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| ATP5D |
|
(source: Drug Bank) |
| ATP2C1 |
|
(source: Drug Bank) |
| ALB |
|
(source: Drug Bank) |
| GABRA1 |
|
(source: Drug Bank) |
| GRIA1 |
|
(source: Drug Bank) |
| GLRA1 |
|
(source: Drug Bank) |
| GNG2 |
|
(source: Drug Bank) |
| MT-ND1 |
|
(source: Drug Bank) |
| NPSR1 |
|
(source: Drug Bank) |
| KCNN4 |
|
(source: Drug Bank) |
| KCNJ3 |
|
(source: Drug Bank) |
| KCNJ6 |
|
(source: Drug Bank) |
| KCNMA1 |
|
(source: Drug Bank) |
| RHO |
|
(source: Drug Bank) |
Reactome Pathways†
- CYP2E1 reactions - (Reactome via Pathway Interaction Database)
- P450 Dehalogenation - (Reactome via Pathway Interaction Database)
A list of non-curated publications that mention this drug along with other drugs is available.
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
|
Malignant Hyperthermia |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.